Constrictive Pericarditis With Preserved Function: How Early to Operate
A confirmed case of constriction, caught while the patient still works full shifts and shows only mild symptoms. The disagreement is between operating while outcomes are best and giving still-active inflammation a real chance to resolve on its own.
J.O., a 45-year-old man, has spent two decades supervising construction crews, most of it spent climbing scaffolding without a second thought, which is exactly why he noticed it when the climbing itself started costing him something it never used to. He can still do the job — full shifts, no time missed — but he's short of breath by the third or fourth flight in a way that wasn't true two months ago. Nine months earlier, he'd had a sharp, positional chest pain that his primary doctor called pericarditis, likely viral, treated with an anti-inflammatory and colchicine for a few weeks until it resolved and he stopped thinking about it entirely.
It hadn't fully resolved. A cardiac MRI ordered to explain his new exertional fatigue shows a thickened pericardium and a ventricular septum that moves abnormally with breathing — a bounce, in the terminology, that reflects a heart constrained on all sides by a rigid sac rather than beating within a normally compliant one. Catheterization confirmed it directly: his right- and left-heart pressures rise and fall in opposite directions with respiration, the discordance that defines constrictive physiology mechanically rather than by inference from imaging alone. His inflammatory markers, checked again now, are lower than they were during the acute episode but haven't fully normalized either, which is its own kind of ambiguous signal — some cases of constriction caught this early, still inflamed rather than purely fibrotic and scarred, soften or even resolve with continued anti-inflammatory therapy rather than needing surgery at all. He has no swelling in his legs, no fluid in his abdomen, and by every functional measure he's still an NYHA class I to II patient managing a full workday. That mildness is precisely the source of the disagreement: pericardiectomy is a real operation with real morbidity, and the guidelines that support it most clearly describe patients considerably sicker than he currently is.
Reviewing confirmed constriction in a mildly symptomatic patient
Surgical outcomes for constrictive pericarditis are strongly tied to preoperative functional class — patients operated on at NYHA class I to II have substantially better perioperative mortality and long-term outcomes than those who wait until class III or IV. Waiting for him to decline defeats the entire purpose of catching this early. True fibrotic constriction doesn't reliably reverse with medical therapy, and delaying risks him crossing into higher-risk territory before anyone acts.
His still-elevated, if improving, inflammatory markers and the recency of his diagnosis are exactly the profile described in the literature as transient constrictive pericarditis. In the largest series, 36 of 212 patients with constrictive physiology — about one in six — resolved on medical therapy alone without pericardiectomy, over an average of roughly eight weeks, and idiopathic or viral disease like his was the single largest contributor to that group. Operating now on someone who might resolve medically exposes him to real surgical risk for a condition that may not turn out to be permanent.
This isn't a case for indefinite watching — it's a case for a defined trial with a clear endpoint, not an open-ended "wait and see."
A defined-duration medical trial is the actual bridge between these two positions. I'd extend his colchicine and consider adding a tapering corticosteroid course, given his mild but persistent CRP elevation, for a fixed window — commonly cited as roughly two to three months in the transient-constriction literature — with serial imaging and hemodynamic reassessment at the end of it, rather than either operating immediately or watching him indefinitely without a plan. The corticosteroid addition is its own real tradeoff worth naming directly to him. Steroids are deliberately second-line in ordinary pericarditis because they raise the recurrence rate and create steroid dependence, which is why the escalation normally runs anti-inflammatory first and steroid later — here we are inverting that order on purpose, for the constriction-specific indication, and the price is that recurrence risk plus impaired wound healing if pericardiectomy does end up being needed.
Agreed: a defined eight-to-twelve-week trial of extended colchicine with a tapering corticosteroid course added given his persistent CRP elevation, serial echocardiogram and MRI at the end of the window, and a standing surgical referral kept open rather than closed.
Not agreed, and the reason the trial window isn't treated as automatic:
Continue medical management, defer surgery, and reassess again at a longer interval.
Proceed to pericardiectomy without waiting out the full trial, on the surgeon's original functional-class-timing argument.